Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy
William J. Sandborn(University of San Diego), Brian G. Feagan(Western University), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), C Gasink, Stephan R. Targan(Cedars-Sinai Medical Center), Jürgen M. Stein(Unknown), Subrata Ghosh(University College Cork), Bin Zou(Third Affiliated Hospital of Guangzhou Medical University), P. Rutgeerts, Willem J.S. de Villiers(Stellenbosch University), Stephen B. Hanauer(Northwestern University), Jewel Johanns(Johnson & Johnson (United States)), Jean‐Frédéric Colombel(Mount Sinai Hospital)
Cited by 186
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k